Researchers evaluated 81 intermediate-risk prostate cancer patients treated at Winthrop University Hospital in Mineola, NY, with a median follow-up of four years, including 24 patients with a minimum of five years of follow-up.

The study found a four-year relapse-free survival rate of 91%, with patients experiencing only mild toxicity with minimal impact on quality of life and immediate-to-rapid return to normal activity.

According to the company, the results support the ability of CyberKnife prostate SBRT to achieve high rates of long-term disease control, while sparing healthy tissue and critical nearby structures, thus minimizing side effects associated with other treatment modalities and preserving patients' quality of life.

The study was presented at the American Urological Association (AUA) meeting in Atlanta.